<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346150</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT RDCRN PIDTC-6902</org_study_id>
    <nct_id>NCT01346150</nct_id>
  </id_info>
  <brief_title>Patients Treated for SCID (1968-Present)</brief_title>
  <official_title>A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Primary Immune Deficiency Treatment Consortium (PIDTC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with a past diagnosis of severe combined immune deficiency (including many cases&#xD;
      of &quot;leaky SCID&quot;, Omenn syndrome, and reticular dysgenesis) who have undergone blood and&#xD;
      marrow transplant, gene therapy, or enzyme replacement in the past may be eligible for this&#xD;
      study. The purpose of study is to look backwards at what has already been done in the. Over&#xD;
      800 patients with SCID are expected to be enrolled, making this one of the largest studies&#xD;
      ever to describe outcomes for patients with SCID treated at many different hospitals around&#xD;
      North America.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the most important components of this study is the &quot;cross sectional&quot; aspect. Patients&#xD;
      who have received their treatments (BMT, gene therapy, enzyme replacement) many years ago are&#xD;
      asked to come back to the hospital where they were treated. During this visit, additional&#xD;
      research bloodwork is drawn, and information is gathered regarding long-term transplant&#xD;
      outcomes such as infections, graft-versus-host disease, autoimmune diseases, and quality of&#xD;
      life. This will allow PIDTC researchers to better understand long-term outcomes from&#xD;
      procedures that occurred many years ago (sometimes over 30 years ago). This will help&#xD;
      researchers to best design new treatments and clinical trials in the future for children with&#xD;
      SCID.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 15, 2011</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective Study - Part 1</measure>
    <time_frame>1, 5, 10, 20, &gt;20 years</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross-Sectional Study - Part 2</measure>
    <time_frame>2 to &gt; 20 years</time_frame>
    <description>Full immune reconstitution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retrospective Study Part 1</measure>
    <time_frame>1 year to &gt; 20 years</time_frame>
    <description>Immune reconstitution and clinical outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrospective Study - Part 1</measure>
    <time_frame>3 months to &gt;20 years</time_frame>
    <description>Engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-Sectional Study - Part 2</measure>
    <time_frame>2 to &gt;20 years</time_frame>
    <description>Current state of lineage-specific chimerism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-Sectional Study - Part 2</measure>
    <time_frame>2 to &gt;20 years</time_frame>
    <description>Current status of health</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1007</enrollment>
  <condition>SCID</condition>
  <condition>ADA-SCID</condition>
  <condition>XSCID</condition>
  <condition>Leaky SCID</condition>
  <condition>Omenn Syndrome</condition>
  <condition>Reticular Dysgenesis</condition>
  <arm_group>
    <arm_group_label>Stratum A -Typical SCID</arm_group_label>
    <description>Typical Severe Combined Immunodeficiency (SCID), Adenosine Deaminase-Deficient ADA SCID, and X-linked SCID (XSCID) who received a transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum B - Atypical SCID</arm_group_label>
    <description>Leaky SCID, Omenn Syndrome, and Reticular Dysgenesis who received a transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum C - SCID w/Non-HCT Treatments</arm_group_label>
    <description>SCID who received Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) or gene therapy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biospecimens may include blood, other tissues (e.g., buccal swab or brushing), and/or bone&#xD;
      marrow.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with diagnosis of SCID or SCID variants treated at Participating Consortium&#xD;
        Centers from 1968-Present&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Strata A, B, and C (Part 1 - Retrospective Study)-&#xD;
&#xD;
          -  Individuals with Severe Combined Immune Deficiency (SCID) diagnosis who:&#xD;
&#xD;
             --were treated at a location participating in this consortium from 1968 until present,&#xD;
             and&#xD;
&#xD;
             --are not enrolled in RDCRN PIDTC-6901 (ClinicalTrials.gov ID: NCT01186913).&#xD;
&#xD;
          -  Subjects who received HCT/GT/ERT prior to the present date are eligible for the&#xD;
             retrospective study. The enrollment criteria for subjects who died prior to definitive&#xD;
             therapy are the same as for Strata A, B and C.&#xD;
&#xD;
        Stratum A, Typical SCID:&#xD;
&#xD;
          -  Individuals who meet the following inclusion criteria and who received HCT are&#xD;
             eligible for enrollment into Stratum A of the study:&#xD;
&#xD;
               -  Absence or very low number of T cells (CD3 T cells &lt; 300/microliter), and no or&#xD;
                  very low T cell function (&lt; 10% of lower limit of normal) as measured by response&#xD;
                  to phytohemagglutinin (PHA) or cells of maternal origin present.&#xD;
&#xD;
               -  If maternal cells are present but the patient does not meet criteria for very low&#xD;
                  T cell function as defined, the assigned reviewers for the potential subject, and&#xD;
                  if necessary, the full PID-SCID RP will review the laboratory report to determine&#xD;
                  if criteria of maternal engraftment are met for Protocol 6902.&#xD;
&#xD;
               -  Laboratory report of testing for maternal engraftment is required, for evaluation&#xD;
                  by the PID-SCID RP.&#xD;
&#xD;
        Stratum B, Leaky SCID, Omenn Syndrome, Reticular Dysgenesis:&#xD;
&#xD;
        Individuals who meet the following criteria are eligible for enrollment into Stratum B of&#xD;
        the study:&#xD;
&#xD;
        Leaky SCID-&#xD;
&#xD;
          -  Maternal lymphocytes tested for and not detected and,&#xD;
&#xD;
          -  Either one or both of the following (a,b):&#xD;
&#xD;
             a) &lt; 50% of lower limit of normal T cell function (as measured by response to PHA OR &lt;&#xD;
             50% of lower limit of normal T cell function as measured by response to CD3/CD28&#xD;
             antibody, b) Absent or &lt; 30% lower limit of normal proliferative responses to candida&#xD;
             and tetanus toxoid antigens postvaccination or exposure,&#xD;
&#xD;
          -  AND at least one of the following (a through e):&#xD;
&#xD;
               1. Reduced number of CD3 T cells,&#xD;
&#xD;
               2. &gt; 80% of CD3+ or CD4 T cells are CD45RO+,&#xD;
&#xD;
          -  AND/OR &gt;80% of CD3+ or CD4+ T cells are,CD62L negative,&#xD;
&#xD;
          -  AND/OR &gt;50% of CD3+ or CD4+ T cells express HLA-DR (at &lt; 4 years of age),&#xD;
&#xD;
          -  AND/OR are oligoclonal T cells. c) Hypomorphic mutation in IL2RG in a male, or&#xD;
             homozygous hypomorphic mutation or compound heterozygosity with at least one&#xD;
             hypomorphic mutation in an autosomal SCID-causing gene.&#xD;
&#xD;
             d) Low TRECs and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is&#xD;
             below the lower limit of normal.&#xD;
&#xD;
             e) Functional testing in vitro supporting impaired, but not absent, activity of the&#xD;
             mutant protein,&#xD;
&#xD;
               -  AND does not meet criteria for Omenn Syndrome,&#xD;
&#xD;
               -  AND does not have known selective loss of lymphocytes, Ataxia- Telangiectasia, or&#xD;
                  congenital heart defect associated with lymphopenia, unless a SCID genotype is&#xD;
                  also present.&#xD;
&#xD;
        Omenn Syndrome (OS):&#xD;
&#xD;
          -  Generalized skin rash,&#xD;
&#xD;
          -  Maternal engraftment tested for and not detected,&#xD;
&#xD;
          -  Absent or low (up to 30% of normal) T cell proliferation to antigens to which the&#xD;
             patient has been exposed.&#xD;
&#xD;
          -  If the proliferation to antigen was not performed, but at least 4 of the following 10&#xD;
             supportive criteria, at least one of which must be among those marked with an asterisk&#xD;
             (*) are present, the patient is eligible: hepatomegaly; splenomegaly; lymphadenopathy;&#xD;
             elevated IgE; elevated absolute eosinophil count; *oligoclonal T cells measured by&#xD;
             CDR3 length or flow cytometry &gt;80% of CD4+ T cells are CD45RO+ ;*proliferation to PHA&#xD;
             is reduced &lt;50% of lower limit of normal or SI &lt;30; *proliferative response in mixed&#xD;
             leukocyte reaction is reduced to increment cpm &lt; 20% or SI &lt;20; hypomorphic mutation&#xD;
             to SCID causing gene; low TRECs and/or percentage of CD 4+/ RA+/CD31+; or&#xD;
             CD4+/RA+/CD62L+ cells below the lower limit of normal.&#xD;
&#xD;
        Reticular Dysgenesis (RD):&#xD;
&#xD;
          -  Absence or very low number of T cells (CD3 T cells &lt;300/microliter),&#xD;
&#xD;
          -  No or very low (&lt;10% of lower limit of normal) T cell function (as measured by&#xD;
             response to phytohemagglutinin (PHA),&#xD;
&#xD;
          -  Severe congenital neutropenia (absolute neutrophil count &lt;200/microliter),&#xD;
&#xD;
          -  AND at least one of the following:&#xD;
&#xD;
               -  Sensorineural deafness and/or absence of granulopoiesis at bone marrow&#xD;
                  examination and/or a deleterious AK2 mutation,&#xD;
&#xD;
               -  absence of granulopoiesis on bone marrow examination; a pathogenic mutation in&#xD;
                  the adenylate kinase 2 (AK2) gene identified.&#xD;
&#xD;
        Stratum C, SCID with Non-HCT Treatments:&#xD;
&#xD;
        -Individuals who meet the following criteria and were treated with PEG-ADA or gene therapy&#xD;
        with autologous modified cells are eligible for enrollment into Stratum C (SCID with&#xD;
        non-HCT treatments) of the study-&#xD;
&#xD;
        - Any SCID patient previously treated with a thymus transplant (includes intention to treat&#xD;
        with HCT, as well as PEG-ADA ERT or gene therapy).&#xD;
&#xD;
        Strata A, B, and C (Part 2 - Cross-Sectional Study):&#xD;
&#xD;
        Patient inclusion criteria for the cross sectional study: Eligibility for Strata A, B and C&#xD;
        are the same as for the retrospective study except that all the patients in the&#xD;
        cross-sectional study are currently surviving and are at least 2 years post the most recent&#xD;
        class of therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Parts 1 and 2 - Retrospective and Cross-Sectional Studies -&#xD;
&#xD;
          -  Lack of appropriate testing to rule out HIV infection after 1997 (p24 antigen or more&#xD;
             sensitive) or other cause of secondary immunodeficiency,&#xD;
&#xD;
          -  Presence of DiGeorge syndrome,&#xD;
&#xD;
          -  Most patients with other PIDs such as nucleoside phosphorylase deficiency, ZAP70&#xD;
             deficiency, CD40 ligand deficiency, NEMO deficiency, XLP, cartilage hair hypoplasia or&#xD;
             ataxia telangiectasia will not meet the inclusion criteria for Stratum A, B, or C&#xD;
             above; however, a patient with one of the above may meet the inclusion criteria for&#xD;
             Stratum B and if so will be included-&#xD;
&#xD;
               -  MHC Class I and MHC Class II antigen deficiency are excluded,&#xD;
&#xD;
               -  Metabolic conditions that imitate SCID or related disorders such as folate&#xD;
                  transporter deficiency, severe zinc deficiency, transcobalamin deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie Haddad, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Montréal, CHU Sainte-Justine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard J. O'Reilly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morton J. Cowan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mattel Children's Hospital UCLA: Division of Pediatric Hematology/Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Salter Packard Children's Hospital at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1278</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Denver:Center for Cancer and Blood Disorders</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital/Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center Genetic Immunotherapy Section</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSM Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University St Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center: Department of Pediatrics</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center: Department of Pediatrics</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center: Department of Pediatrics, Division of Allergy/Immunology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University: Pediatric Hematology/Oncology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center: Clinical Research Division and Pediatric Stem Cell Transplantation Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin/ American Family Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705-2275</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-4874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children (SickKids)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1XB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St. Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rarediseasesnetwork.org/cms/pidtc</url>
    <description>Primary Immune Deficiency Treatment Consortium (PIDTC)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://ncats.nih.gov/</url>
    <description>National Center for Advancing Translational Sciences (NCATS)</description>
  </link>
  <reference>
    <citation>Griffith LM, Cowan MJ, Kohn DB, Notarangelo LD, Puck JM, Schultz KR, Buckley RH, Eapen M, Kamani NR, O'Reilly RJ, Parkman R, Roifman CM, Sullivan KE, Filipovich AH, Fleisher TA, Shearer WT. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol. 2008 Dec;122(6):1087-96. doi: 10.1016/j.jaci.2008.09.045. Epub 2008 Nov 6.</citation>
    <PMID>18992926</PMID>
  </reference>
  <results_reference>
    <citation>Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31;371(5):434-46. doi: 10.1056/NEJMoa1401177.</citation>
    <PMID>25075835</PMID>
  </results_reference>
  <results_reference>
    <citation>Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, Griffith LM, Kohn DB, O'Reilly RJ, Fleisher TA, Pai SY, Martinez CA, Buckley RH, Cowan MJ. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014 Apr;133(4):1092-8. doi: 10.1016/j.jaci.2013.09.044. Epub 2013 Nov 28.</citation>
    <PMID>24290292</PMID>
  </results_reference>
  <results_reference>
    <citation>Haddad E, Allakhverdi Z, Griffith LM, Cowan MJ, Notarangelo LD. Survey on retransplantation criteria for patients with severe combined immunodeficiency. J Allergy Clin Immunol. 2014 Feb;133(2):597-9. doi: 10.1016/j.jaci.2013.10.022. Epub 2013 Dec 10.</citation>
    <PMID>24331379</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Shearer WT, Burroughs LM, Torgerson TR, Decaluwe H, Haddad E; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol. 2016 Aug;138(2):375-85. doi: 10.1016/j.jaci.2016.01.051. Epub 2016 Apr 22. Review.</citation>
    <PMID>27262745</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol. 2014 Feb;133(2):335-47. doi: 10.1016/j.jaci.2013.07.052. Epub 2013 Oct 15.</citation>
    <PMID>24139498</PMID>
  </results_reference>
  <results_reference>
    <citation>Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Shearer WT, O'Reilly RJ, Fleisher TA, Pai SY, Hanson IC, Pulsipher MA, Fuleihan R, Filipovich A, Goldman F, Kapoor N, Small T, Smith A, Chan KW, Cuvelier G, Heimall J, Knutsen A, Loechelt B, Moore T, Buckley RH. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013 Oct;33(7):1156-64. doi: 10.1007/s10875-013-9917-y. Epub 2013 Jul 2.</citation>
    <PMID>23818196</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009 Dec;124(6):1152-60.e12. doi: 10.1016/j.jaci.2009.10.022.</citation>
    <PMID>20004776</PMID>
  </results_reference>
  <results_reference>
    <citation>Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB, Notarangelo LD, Grunebaum E. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. 2019 Mar;143(3):852-863. doi: 10.1016/j.jaci.2018.08.024. Epub 2018 Sep 5. Review.</citation>
    <PMID>30194989</PMID>
  </results_reference>
  <results_reference>
    <citation>Miggelbrink AM, Logan BR, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Abdel-Azim H, Prockop SE, Shyr D, Decaluwe H, Hanson IC, Gillio A, Dávila Saldaña BJ, Eibel H, Hopkins G, Walter JE, Whangbo JS, Kohn DB, Puck JM, Cowan MJ, Griffith LM, Haddad E, O'Reilly RJ, Notarangelo LD, Pai SY. B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood. 2018 Jun 28;131(26):2967-2977. doi: 10.1182/blood-2017-10-809822. Epub 2018 May 4.</citation>
    <PMID>29728406</PMID>
  </results_reference>
  <results_reference>
    <citation>Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, Small TN, Chaisson J, Dvorak CC, Murnane M, Kapoor N, Abdel-Azim H, Hanson IC, Martinez C, Bleesing JJH, Chandra S, Smith AR, Cavanaugh ME, Jyonouchi S, Sullivan KE, Burroughs L, Skoda-Smith S, Haight AE, Tumlin AG, Quigg TC, Taylor C, Dávila Saldaña BJ, Keller MD, Seroogy CM, Desantes KB, Petrovic A, Leiding JW, Shyr DC, Decaluwe H, Teira P, Gillio AP, Knutsen AP, Moore TB, Kletzel M, Craddock JA, Aquino V, Davis JH, Yu LC, Cuvelier GDE, Bednarski JJ, Goldman FD, Kang EM, Shereck E, Porteus MH, Connelly JA, Fleisher TA, Malech HL, Shearer WT, Szabolcs P, Thakar MS, Vander Lugt MT, Heimall J, Yin Z, Pulsipher MA, Pai SY, Kohn DB, Puck JM, Cowan MJ, O'Reilly RJ, Notarangelo LD. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood. 2018 Oct 25;132(17):1737-1749. doi: 10.1182/blood-2018-03-840702. Epub 2018 Aug 28.</citation>
    <PMID>30154114</PMID>
  </results_reference>
  <results_reference>
    <citation>Dvorak CC, Haddad E, Buckley RH, Cowan MJ, Logan B, Griffith LM, Kohn DB, Pai SY, Notarangelo L, Shearer W, Prockop S, Kapoor N, Heimall J, Chaudhury S, Shyr D, Chandra S, Cuvelier G, Moore T, Shenoy S, Goldman F, Smith AR, Sunkersett G, Vander Lugt M, Caywood E, Quigg T, Torgerson T, Chandrakasan S, Craddock J, Dávila Saldaña BJ, Gillio A, Shereck E, Aquino V, DeSantes K, Knutsen A, Thakar M, Yu L, Puck JM. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). J Allergy Clin Immunol. 2019 Jan;143(1):405-407. doi: 10.1016/j.jaci.2018.08.027. Epub 2018 Sep 5.</citation>
    <PMID>30193840</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

